Kathryn Lumb

Representative Experience

• Represented HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science, in a $1.1B+ agreement to exclusively license its Galectin-9 program and grant an exclusive option to its CXCR5 and CCR8 programs.
• Represented Ginkgo Bioworks, the organism company, in a gene therapy collaboration and license agreement with Biogen to redefine the industry standard for manufacturing and develop a next-generation recombinant adeno-associated virus (AAV) production platform, for an upfront payment of $5 million and up to $115 million in future milestone payments.
• Represented Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent estate, in a global collaboration and license agreement with Takeda Pharmaceutical Company Limited.
• Represented Anji Pharma in a License Transfer and Royalty Agreement with LipimetiX Development, transferring all rights worldwide (in addition to the previously sublicensed territory of China, Hong Kong and Taiwan) to their Apo E mimetic peptides program, for upfront cash payments and a royalty on future commercial sales. 
• Represented Dogma Therapeutics in the sale of its oral PCSK9 program to global biopharmaceutical company AstraZeneca for upfront as well as downstream payments linked to global regulatory and commercial milestones. 
• Represented Dicerna Pharmaceuticals (Nasdaq: DRNA) in a global collaboration agreement with Novo Nordisk A/S (NYSE: NVO) to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases. Under the terms of the agreement, Dicerna will receive an upfront payment of $175 million, a $50 million equity investment and up to $357.5 million per target in development, regulatory, and commercialization milestone payments.
• Represented Bridge Biotherapeutics in a collaboration and license agreement in excess of €1.1 billion in upfront and milestone payments, plus royalties, with Boehringer Ingelheim to develop Bridge Biotherapeutics’ autotaxin inhibitor BBT-877 for idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung diseases. 
• Represented LegoChem Bio in a $400+ million multi-target research collaboration and license agreement with Takeda Pharmaceutical Company Limited (NYSE: TAK).
• Advised Applied Genetic Technologies Corporation (Nasdaq: AGTC) in a strategic collaboration with Otonomy, Inc. (Nasdaq: OTIC) to co-develop and co-commercialize an adeno-associated virus (AAV)-based gene therapy.

Professional Experience

• Northeast Intellectual Property, Co-founder
• Elan Pharmaceuticals, Chief Intellectual Property Officer
• Pfizer Inc., Assistant General Counsel